&nbsp;

Jan 2025

Drug

daSATinib

Other Name(s): Sprycel®

Quick Link(s):

Feb 2025

Drug

degarelix

Other Name(s): Firmagon®

Quick Link(s):

Feb 2025

Drug

dacarbazine

Quick Link(s):

Jun 2025

Drug

pegylated liposomal DOXOrubicin

Other Name(s): Caelyx®

Quick Link(s):

Sep 2025

Drug

daBRAFenib

Other Name(s): Tafinlar®

Quick Link(s):

Jun 2025

Drug

pomalidomide

Other Name(s): Pomalyst®

Quick Link(s):

Apr 2025

Drug

pembrolizumab

Other Name(s): Keytruda®

Quick Link(s):

Sep 2025

Regimen

DASA

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

daSAtinib - Ph+ CML in the chronic phase, with specific criteria

Exceptional Access Program

daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria

, Collapse Show fewer tags

Drugs Used:

daSATinib

... Show more tags

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

DCRB

Cancer Type:

Sarcoma,

Soft Tissue,

Skin,

Melanoma

, Collapse Show fewer tags

Intent: Palliative

Drugs Used:

dacarbazine

... Show more tags

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

PGLDX

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Funding:

New Drug Funding Program

Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer

New Drug Funding Program

Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer